Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the duration of the viral shedding in hematology and oncology patients after a respiratory tract viral infection. This duration has not been much studied in that population whereas it is probably longer than that in immunocompetent patients. Thereby it may be a source of transmission amongst these immunocompromised patients.

Detailed Description
-----------------
The development of multiplex polymerase chain reaction (PCR) tests has greatly improved the diagnosis of respiratory tract viral infections by increasing its sensitivity and the diversity of viral species detected. However, there are few data concerning respiratory tract viral infections amongst hematology and oncology patients. Especially, the duration of viral shedding following an infection has not been much studied whereas it is a source of inter-individual transmission between immunocompromised patients who are more likely to develop severe disease. Studies conducted so far concerned mainly hematology patients. They have shown that viral carriage could last up to one month and a half in some patients with hematological malignancy. The aim of this study is to determine the duration of the viral shedding in patients from hematology and oncology units after a respiratory tract viral infection for the ten main viruses involved in order to better manage these infections and to better prevent their transmission.

Official Title
-----------------
Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients

Conditions
-----------------
Respiratory Tract Viral Infection

Intervention / Treatment
-----------------
* Diagnostic Test: nasal swabs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with solid organ cancer or haematological malignancy with or without chemotherapy Having symptoms of upper and/or lower respiratory tract infection Virus detected by PCR in nasal sample Signature of consent Exclusion Criteria: Hematological stem cell and solid organ recipients No health insurance protected people

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: Iterative nasal swabs will be performed to screen for virus shedding
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: nasal swabs|Iterative nasal swabs will be performed to screen for virus shedding|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Nasal carriage of virus after a viral respiratory tract infection | Iterative nasal swab to assess the duration of that carryiage | Up to 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of upper and lower respiratory tract infections |  | 2 years | 
| Prevalence of viral coinfections |  | 2 years | 
| Prevalence of bacterial coinfections |  | 2 years | 
| transmission of respiratory tract viral infections by relatives | with a survey filled by the patient | 2 years | 
| respiratory complications due to respiratory tract viral infections |  | 2 years | 
| extra-pulmonary symptoms due to respiratory tract viral infections |  | 2 years | 
| effect of influenza vaccine on viral shedding |  | 2 years | 
| risk factors to do severe form of respiratory tract infection |  | 2 years | 
| nosocomial transmission of respiratory tract viral infection |  | 2 years | 
| delay of chemotherapy due to respiratory infection |  | 2 years | 
| survival after a respiratory tract viral infection |  | 30 days | 
| TTV viral load as a marker of immunodepression in oncology and hematology patients | TTV viral load at each visit | 2 years | 
| Correlation between TTV viral load and duration of viral shedding and severity of respiratory tract infection |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
respiratory tract infections, virus shedding, cancer, Immunocompromised Host